In another randomized trial (VICTORIA), in a cohort of 5050 heart failure patients with reduced LVEF <45% in NYHA class II-IV with elevated NT-proBNP values, 2524 patients received vericiguat given together with standard heart failure therapy for more than ten months. The gene discussed is NPPB; the disease is heart failure.